NCT01651676

Brief Summary

The purpose of this study is to estimate the capacity of the auto-questionnaire of quality of life, VQ11, to follow the evolution of patients with COPD (Chronic obstructive pulmonary disease) in stable state (without exacerbation in the previous 6 weeks) (3 months +/-15 days) during the implementation of a LABD (Long-acting bronchodilator) treatment. The main objective is to compare the total Score of the VQ11 auto-questionnaire before and after LABD. A decrease of 5 points of the total score mimicking an improvement in the quality of life linked to health, specifically in the COPD.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
57

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Feb 2013

Typical duration for not_applicable

Geographic Reach
1 country

17 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

June 29, 2012

Completed
28 days until next milestone

First Posted

Study publicly available on registry

July 27, 2012

Completed
6 months until next milestone

Study Start

First participant enrolled

February 1, 2013

Completed
2.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2015

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2015

Completed
Last Updated

November 19, 2025

Status Verified

November 1, 2025

Enrollment Period

2.8 years

First QC Date

June 29, 2012

Last Update Submit

November 17, 2025

Conditions

Keywords

VQ11 questionnaireCOPDLBD

Outcome Measures

Primary Outcomes (1)

  • VQ11 score

    To compare changes of total Score of the VQ11 auto-questionnaire before and after LABD (decrease of 5 points of the total score mimicking an improvement in the quality of life linked to health, specifically in the COPD).

    V1 (at baseline), V2 (3 months after V1)

Secondary Outcomes (9)

  • VQ11 and visual analogical scale regarding daily activity

    V1 (at baseline), V2 (3 months after V1)

  • RFE

    V1 (at baseline), V2 (3 months after V1)

  • VQ11 sub-scores

    V1 (at baseline), V2 (3 months after V1)

  • Likert scales

    V2 (3 months after V1)

  • VQ11 and visual analogical scales regarding dyspnoea

    V1 (at baseline), V2 (3 months after V1)

  • +4 more secondary outcomes

Study Arms (1)

COPD arm

EXPERIMENTAL

VQ11 validation: Stage II, III or IV COPD patients justifying a LABD will benefit from the studied VQ11 questionnaire

Other: VQ11 validation

Interventions

Two visits per patient are planned: V1 and V2. For each visit, the pulmonologists ask the patients participating in the study to fill out the VQ11 questionnaire, which will be correlated to the other parameters (Likert scale, IPAQ, RFE, SGRQ,...) LABD treatment consist in β 2 agonists or anticholinergic drug.

COPD arm

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • COPD patient with stage II, III ou IV justifying a LABD
  • Patient in stable state (without exacerbation in the previous 6 weeks)
  • Clinical criteria: dyspnoea stage I ou more (MMRC scale)
  • Adult over 18 years old.
  • Patients naïve from LABD treatment.

You may not qualify if:

  • Other associated pathology (bronchiectasia...)
  • Heart disorder with a prevailing role in the dyspnoea
  • Cardiac decompensation in the previous year
  • Pregnancy and lactating
  • Women in genital activity without efficient contraception method (IUD or estrogen-progestin pill)
  • Lack of social insurance
  • Patient non compliant to protocol, at the investigator's appreciation
  • Simultaneous participation to other clinical trial.
  • adult under judicial protection (tutor or curator).

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (17)

Clinique de l'Europe

Amiens, 80000, France

Location

CHU Amiens Nord

Amiens, 80054, France

Location

CHU Amiens Sud

Amiens, 80054, France

Location

Centre Hospitalier de Chauny

Chauny, 02300, France

Location

Centre Hospitalier de Compiègne

Compiègne, 60200, France

Location

Centre Médical

Compiègne, 60200, France

Location

CH Creil

Creil, 60109, France

Location

Centre Médical

Denain, 59220, France

Location

CH de DOUAI

Douai, 59507, France

Location

Hopital Jacques MONOD

Le Havre, 76083, France

Location

Centre Médical

Le Havre, 76600, France

Location

CHRU de Lille

Lille, 59037, France

Location

Hopital Maison Blanche

Reims, 51092, France

Location

CHU de Rouen

Rouen, 76000, France

Location

Centre hospitalier de St Quentin

Saint-Quentin, 02321, France

Location

Zac Gouraud

Soissons, 02200, France

Location

Résidence Saint Michel

Valenciennes, 59300, France

Location

Related Publications (1)

  • https://doi.org/10.1016/j.rmr.2015.10.647 Évaluation par auto-questionnaire de qualité de vie VQ11 de l'impact d'un traitement bronchodilatateur dans la BPCO en pratique pneumologique Revue des Maladies Respiratoires Volume 33, Supplement, January 2016, Page A34

    RESULT

MeSH Terms

Conditions

Pulmonary Disease, Chronic Obstructive

Condition Hierarchy (Ancestors)

Lung Diseases, ObstructiveLung DiseasesRespiratory Tract DiseasesChronic DiseaseDisease AttributesPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

  • Charles DAYEN, MD

    University Hospital of Amiens

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
SCREENING
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 29, 2012

First Posted

July 27, 2012

Study Start

February 1, 2013

Primary Completion

December 1, 2015

Study Completion

December 1, 2015

Last Updated

November 19, 2025

Record last verified: 2025-11

Locations